Antiemetics · Reglan
Metoclopramide (Reglan) Side Effects: The CYP2D6 Connection
Metoclopramide helps with nausea and slow stomach emptying, but it can cause movement side effects, and that risk goes up when the drug builds up. The CYP2D6 enzyme is part of why levels vary.
Metoclopramide, sold as Reglan, is used for nausea, reflux, and slow stomach emptying. It is effective, but it carries a real risk of movement-related side effects, especially with higher doses or longer use. How much metoclopramide builds up in your body depends in part on the enzyme CYP2D6, whose speed varies from person to person for genetic reasons.
Why metoclopramide side effects vary
Movement side effects are the main concern
Metoclopramide can cause restlessness, muscle spasms, and, with longer use, a movement disorder called tardive dyskinesia that may not fully reverse. This is why it carries a boxed warning and is usually limited to short courses.
Dose and duration drive the risk
The risk of movement side effects rises with higher doses and with use beyond about twelve weeks. Keeping the dose low and the course short is the main way to reduce that risk.
Age, kidney function, and other drugs matter
Older adults, people with reduced kidney function, and those taking other drugs that affect dopamine or block CYP2D6 are at higher risk. Levels can climb when clearance is reduced for any of these reasons.
Your CYP2D6 genetics set part of the clearance
CYP2D6 helps break metoclopramide down, so poor metabolizers tend to reach higher levels on a given dose, which adds to the side-effect risk.
Metoclopramide's most serious side effects involve movement, and they become more likely as drug levels rise, which is exactly what tends to happen in CYP2D6 poor metabolizers.
How your genetics can play a role
The gene that stands out for metoclopramide is CYP2D6, the same enzyme involved in many antidepressants, opioids, and antipsychotics.
| Gene | What it affects |
|---|---|
| CYP2D6 | CYP2D6 helps clear metoclopramide, and FDA labeling notes that CYP2D6 poor metabolizers reach higher drug concentrations and a higher risk of adverse reactions.[1] CYP2D6 is recognized in pharmacogenomic labeling for metoclopramide.[2] Because the same enzyme handles so many drugs, a CYP2D6 result is useful across your medication list. |
If you are a CYP2D6 normal metabolizer, standard short-course dosing applies. If you are a poor metabolizer, metoclopramide clears more slowly and reaches higher levels, so labeling advises reducing the dose to lower the risk of adverse reactions, including the movement side effects the drug is known for.[1] Keeping the course short remains important regardless of metabolizer type. Knowing your CYP2D6 status adds one more safety input, especially if you need metoclopramide for more than a brief period.[3]
Want to know what your genetics say about how you'll respond to Metoclopramide?
A Gene2Rx report reads your own DNA to show how it may affect your response to Metoclopramide and your other medications.
Find out todayWhen to consider pharmacogenetic testing
Pharmacogenetic testing is worth considering if you have had movement side effects or other strong reactions to metoclopramide, if you may need it for more than a short course, or if you have had similar trouble with other CYP2D6 medications. The result also helps guide many other prescriptions.
What you can do next
- Use metoclopramide at the lowest effective dose and for the shortest time your doctor recommends.
- Report any restlessness, muscle stiffness, or unusual movements right away, since early action matters for movement side effects.
- Tell your doctor about other medications, especially CYP2D6 blockers and other drugs that affect dopamine.
- Consider pharmacogenetic testing to learn whether your CYP2D6 genetics raise your metoclopramide levels.
Related medications
Related guides
- Zofran Not Working for Nausea? The CYP2D6 Explanation
- 23andMe Drug Response: What You'll Actually See in a Report From Your Data
- 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
- AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
- Atomoxetine Not Working? Why Strattera Might Not Be Helping Your ADHD
- Codeine Not Working for Pain? Your Genetics May Be Why
Frequently asked questions
Why is metoclopramide limited to short-term use?
The risk of tardive dyskinesia, a movement disorder that may not fully reverse, rises with higher doses and with use beyond about twelve weeks. Keeping the course short is the main way to reduce that risk, which is why metoclopramide carries a boxed warning.
Is Reglan the same as metoclopramide?
Yes. Reglan is a brand name for metoclopramide, so the same CYP2D6 considerations apply across brand and generic versions.
Does being a CYP2D6 poor metabolizer mean I cannot take metoclopramide?
Not necessarily. It means you may reach higher drug levels on a standard dose, so your doctor may use a lower dose and watch more closely for side effects. The short-course principle still applies to everyone, and a CYP2D6 result is one input your doctor uses to dose it more safely.
References
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling (2024). fda.gov
- U.S. Food and Drug Administration. Table of Pharmacogenetic Associations (2024). fda.gov
- Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines. cpicpgx.org
Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change a medication without medical supervision.